Kastrationsresistentes Prostatakarzinom 2011

Zusammenfassung

Das Verständnis für die Enstehungsmechanismen und die Behandlung des kastrationsresistenten Prostatakarzinom erfährt derzeit grundlegende Veränderungen. Neue Medikamente wie der CYP-17-Inhibitor Abiraterone haben gezeigt, dass auch im vermeintlich „hormonrefraktären“ Stadium, der Androgenrezeptor eine wesentliche Rolle für die Progression der Erkrankung spielt. Die Umbenennung in kastrationsresistentes Prostatakarzinom ist ein Ausdruck dieser Erkenntnis. Hier wird ein Überblick über den derzeitigen Stand der Medikamenten Entwicklung, die Behandlungsmöglichkeiten sowie über zukünftige Trends gegeben. 

Abstract

Our understanding of – as well as our approach to – castration resistant prostate cancer is currently undergoing major changes. New drugs like the CYP-17 inhibitor abiraterone have shown that even in the “hormone refractory” stage the progression of prostate cancer is still driven by signaling of the androgen receptor. Changing the term to castration resistant prostate cancer is one consequence of these new insights. Here we give an overview on the current situation of drug development, therapeutic consequences and future trends. 

Schlüsselwörter

Prostatakarzinom - medikamentöse Therapie - Chemotherapie - Immuntherapie - gezielte Therapie

Key words

prostate cancer - medical treatment - chemotherapy - immune therapy - targeted therapy

Literatur

• 1 Edwards J, Bartlett J M. The androgen receptor and signal-transduction pathways in hormone-refractory prostate cancer. Part 1: Modifications to the androgen receptor.  BJU Int. 2005;  95 1320-1326
• 2 Edwards J, Bartlett J M. The androgen receptor and signal-transduction pathways in hormone-refractory prostate cancer. Part 2: Androgen-receptor cofactors and bypass pathways.  BJU Int. 2005;  95 1327-1335
• 3 Edwards J et al. Androgen receptor gene amplification and protein expression in hormone refractory prostate cancer.  Br J Cancer. 2003;  89 552-556
• 4 Chen C D. et al . Molecular determinants of resistance to antiandrogen therapy.  Nat Med. 2004;  10 33-39
• 5 McDonnell T J et al. Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer.  Cancer Res. 1992;  52 6940-6944
• 6 Haldar S, Basu A, Croce C M. Bcl2 is the guardian of microtubule integrity.  Cancer Res. 1997;  57 229-233
• 7 Attard G et al. Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer.  J Clin Oncol. 2009;  27 3742-3748
• 8 Attard G. et al . Antitumor activity with CYP17 blockade indicates that castration-resistant prostate cancer frequently remains hormone driven.  Cancer Res. 2009;  69 4937-4940
• 9 Schroder F H. Progress in understanding androgen-independent prostate cancer (AIPC): a review of potential endocrine-mediated mechanisms.  Eur Urol. 2008;  53 1129-1137
• 10 Attard G et al. Phase I Clinical Trial of a Selective Inhibitor of CYP17, Abiraterone Acetate, Confirms That Castration-Resistant Prostate Cancer Commonly Remains Hormone Driven.  J Clin Oncol. 2007;  15 9749
• 11 Scher H I et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group.  J Clin Oncol. 2008;  26 1148-1159
• 12 Smith M R et al. Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer.  J Clin Oncol. 2005;  23 2918-2925
• 13 Falcone A et al. Suramin in combination with weekly epirubicin for patients with advanced hormone-refractory prostate carcinoma.  Cancer. 1999;  86 470-476
• 14 Culine S et al. Evaluation of estramustine phosphate combined with weekly doxorubicin in patients with androgen-independent prostate cancer.  Am J Clin Oncol. 1998;  21 470-474
• 15 Ryan C J, Small E J. Secondary hormonal manipulations in prostate cancer.  Curr Oncol Rep. 2005;  7 228-233
• 16 Taylor C D, Elson P, Trump D L. Importance of continued testicular suppression in hormone-refractory prostate cancer.  J Clin Oncol. 1993;  11 2167-2172
• 17 Hussain M et al. Effects of continued androgen-deprivation therapy and other prognostic factors on response and survival in phase II chemotherapy trials for hormone-refractory prostate cancer: a Southwest Oncology Group report.  J Clin Oncol. 1994;  12 1868-1875
• 18 Kelly W K, Scher H I. Prostate specific antigen decline after antiandrogen withdrawal: the flutamide withdrawal syndrome.  J Urol. 1993;  149 607-609
• 19 Nieh P T. Withdrawal phenomenon with the antiandrogen casodex.  J Urol. 1995;  153 (3 Pt 2) 1070-1072 discussion 1072-1073
• 20 Small E J et al. Antiandrogen Withdrawal Alone or in combination with Ketoconazole in Androgen-Independant Prostate Cancer Patients: A Phase III Trial (CALGB 9583).  J Clin Oncol. 2004;  22 1026-1033
• 21 Kojima S et al. Alternative antiandrogens to treat prostate cancer relapse after initial hormone therapy.  J Urol. 2004;  171 (2 Pt 1) 679-683
• 22 Miyake H, Hara I, Eto H. Clinical outcome of maximum androgen blockade using flutamide as second-line hormonal therapy for hormone-refractory prostate cancer.  BJU Int. 2005;  96 791-795
• 23 Orlando M et al. Low-dose continuous oral fosfestrol is highly active in ‘hormone-refractory’ prostate cancer.  Ann Oncol. 2000;  11 177-181
• 24 Smith D C et al. A phase II trial of oral diethylstilbesterol as a second-line hormonal agent in advanced prostate cancer.  Urology. 1998;  52 257-260
• 25 Kitamura T. Necessity of re-evaluation of estramustine phosphate sodium (EMP) as a treatment option for first-line monotherapy in advanced prostate cancer.  Int J Urol. 2001;  8 33-36
• 26 Gunnarsson P O et al. Impairment of estramustine phosphate absorption by concurrent intake of milk and food.  Eur J Clin Pharmacol. 1990;  38 189-193
• 27 Hirano D et al. Prospective study of estramustine phosphate for hormone refractory prostate cancer patients following androgen deprivation therapy.  Urol Int. 2005;  75 43-49
• 28 Denis L. European Organization for Research and Treatment of Cancer (EORTC) prostate cancer trials, 1976–1996.  Urology. 1998;  51 (S 5A) 50-57
• 29 Cordia C et al. Ketokonazol / hydrocortisone versus estramustinphosphate in the management of PSA progression following primary androgen deprivation for metastatic prostate cancer.  J Clin Oncol. 2005;  23 Abs. No. 4668
• 30 Eichenberger T, Trachtenberg J. Effects of high-dose ketoconazole in patients with androgen-independent prostatic cancer.  Am J Clin Oncol. 1988;  11 (S 2) 104-107
• 31 Wilkinson S, Chodak G. An evaluation of intermediate-dose ketoconazole in hormone refractory prostate cancer.  Eur Urol. 2004;  45 581-584 discussion 585
• 32 Bono J S et al. Anti-tumor activity of abiraterone acetate (AA), a CYP17 inhibitor of androgen synthesis, in chemotherapy naive and docetaxel pre-treated castration resistant prostate cancer (CRPC).  J Clin Oncol. 2008;  26 Suppl Abstr. 5005
• 33 Eisenberger M A et al. A reevaluation of nonhormonal cytotoxic chemotherapy in the treatment of prostatic carcinoma.  J Clin Oncol. 1985;  3 827-841
• 34 Tannock I F, Osoba D, Stockler M. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone resistant prostate cancer: A canadian randomised trial with palliative endpoints.  J Clin Oncol. 1996;  14 1756-1764
• 35 Petrylak D P. Docetaxel (Taxotere) in hormone-refractory prostate cancer.  Semin Oncol. 2000;  27 2 (S 3) 24-29
• 36 Picus J, Schultz M. Docetaxel (Taxotere) as monotherapy in the treatment of hormone-refractory prostate cancer: preliminary results.  Semin Oncol. 1999;  26 5 (S 17) 14-18
• 37 Tannock I F et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.  N Engl J Med. 2004;  351 1502-1512
• 38 Petrylak D P et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.  N Engl J Med. 2004;  351 1513-1520
• 39 Smaletz O et al. Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration.  J Clin Oncol. 2002;  20 3972-3982
• 40 Halabi S et al. Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer.  J Clin Oncol. 2003;  21 1232-1237
• 41 Small E J et al. Results of a Placebo-Controlled Phase III Trial of Immunotherapy with APC8015 for Patients with Hormone Refractory Prostate Cancer (HRPC).  J Clin Oncol. 2005;  23 Abs. No. 4500
• 42 Berruti A et al. Metabolic bone disease induced by prostate cancer: rationale for the use of bisphosphonates.  J Urol. 2001;  166 2023-2031
• 43 Saad F et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma.  J Natl Cancer Inst. 2002;  94 1458-1468
• 44 Marx R E. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic.  J Oral Maxillofac Surg. 2003;  61 1115-1117
• 45 Bamias A et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors.  J Clin Oncol. 2005;  23 8580-8587
• 46 Smith M R et al. Denosumab in men receiving androgen-deprivation therapy for prostate cancer.  N Engl J Med. 2009;  361 745-755
• 47 Tran C et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer.  Science. 2009;  324 787-790
• 48 Scher H I et al. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 study.  Lancet. 2010;  375 1437-1446
• 49 Nilsson S et al. Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study.  Lancet Oncol. 2007;  8 587-594
• 50 Chi K N et al. Randomized phase II study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castration-resistant prostate cancer.  J Clin Oncol. 2010;  28 4247-4254
• 51 Kantoff P W et al. Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer.  J Clin Oncol. 2010;  28 1099-1105
• 52 Yu E Y et al. Phase II study of dasatinib in patients with metastatic castration-resistant prostate cancer.  Clin Cancer Res. 2009;  15 7421-7428
• 53 Small E J et al. A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer.  Clin Cancer Res. 2007;  13 1810-1815
• 54 Madan R A et al. Overall survival (OS) analysis of a phase l trial of a vector-based vaccine (PSA-TRICOM) and ipilimumab (Ipi) in the treatment of metastatic castration-resistant prostate cancer (mCRPC).  J Clin Oncol. 2010;  28 (S 15) (Abstr. 2550)